Life Sciences

OIA launches project to produce alternative protein from dates
20 February 2022

OIA launches project to produce alternative protein from dates

Focusing on its role in attracting foreign investments and advanced technologies to the sultanate, Oman Investment Authority (OIA) has signed an agreement with US-based...

Read more
Maat Pharma and Skyepharma have entered a partnership to establish the first exclusive Microbiome Ecosystem Therapies cGMP Manufacturing Facility in France
14 February 2022

Maat Pharma and Skyepharma have entered a partnership to establish the first exclusive Microbiome Ecosystem Therapies cGMP Manufacturing Facility in France

MaaT Pharma (EURONEXT: MAAT), a French clinical-stage biotech (Phase 3) and a pioneer in the development of microbiome-based ecosystem therapies dedicated to improving survival...

Read the press release
The start-up La Vie™ raises €25M and sets out to conquer the world with its new generation of plant-based meat
19 January 2022

The start-up La Vie™ raises €25M and sets out to conquer the world with its new generation of plant-based meat

The first record raising of €25M in Series A financing from investment funds led by Seventure, and international celebrities that are committed to protecting the planet. This...

Read the press release
Dermala Awarded Grand Prize in Inaugural Colgate Connect Challenge
13 January 2022

Dermala Awarded Grand Prize in Inaugural Colgate Connect Challenge

DERMALA, a consumer dermatology company that develops novel treatments for chronic skin conditions, announces the brand's Grand Prize recognition in the global pitch...

Read more
MaaT Pharma announces successful Initial Public Offering on the regulated market of Euronext Paris
3 November 2021

MaaT Pharma announces successful Initial Public Offering on the regulated market of Euronext Paris

MaaT Pharma S.A. ("MaaT Pharma" or the “Company“), a French clinical-stage biotech and a pioneer in the development of microbiome2-based ecosystem therapies dedicated to...

Read the press release
Axial Therapeutics Receives FDA Clearance of IND Application and Initiates Phase 2b Trial for AB-2004, Lead Gut-Targeted, Molecular Therapeutic for the Treatment of Irritability in Autism Spectrum Disorder
27 October 2021

Axial Therapeutics Receives FDA Clearance of IND Application and Initiates Phase 2b Trial for AB-2004, Lead Gut-Targeted, Molecular Therapeutic for the Treatment of Irritability in Autism Spectrum Disorder

Axial Therapeutics, a clinical-stage biopharmaceutical company dedicated to improving the lives of people with neurological disorders and diseases, today announced that the...

Read the press release
BiomX Announces Agreement with Maruho Co., Ltd. for Atopic Dermatitis Product Candidate BX005
13 October 2021

BiomX Announces Agreement with Maruho Co., Ltd. for Atopic Dermatitis Product Candidate BX005

BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage cocktails that target...

Read the press release
Axial Therapeutics Raises $37.25 Million in Series C Financing to Advance its Pipeline of Gut-Targeted Small Molecule Drugs for Neurological Diseases and Disorders
13 October 2021

Axial Therapeutics Raises $37.25 Million in Series C Financing to Advance its Pipeline of Gut-Targeted Small Molecule Drugs for Neurological Diseases and Disorders

Axial Therapeutics, a clinical-stage biopharmaceutical company dedicated to improving the lives of people with neurological diseases, today announced the completion of a $37.25...

Read more
Vedanta Announces Positive Topline Phase 2 Data for VE303 in High- Risk C. difficile Infection and Exercise of $23.8 Million Option by BARDA
5 October 2021

Vedanta Announces Positive Topline Phase 2 Data for VE303 in High- Risk C. difficile Infection and Exercise of $23.8 Million Option by BARDA

Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today announced that its Phase...

Read the press release